% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lago:285710,
      author       = {C. Lago and A. Federico$^*$ and G. Leva and N. L. Mack$^*$
                      and B. Schwalm$^*$ and C. Ballabio and M. Gianesello and L.
                      Abballe and I. Giovannoni and S. Reddel and S. Rossi and N.
                      Leone and A. Carai and A. Mastronuzzi and A. Bisio and A.
                      Soldano and C. Quintarelli and F. Locatelli and M. Kool$^*$
                      and E. Miele and L. Tiberi},
      title        = {{P}atient- and xenograft-derived organoids recapitulate
                      pediatric brain tumor features and patient treatments.},
      journal      = {EMBO molecular medicine},
      volume       = {15},
      number       = {12},
      issn         = {1757-4676},
      address      = {Heidelberg},
      publisher    = {EMBO Press},
      reportid     = {DKFZ-2023-02518},
      pages        = {e18199},
      year         = {2023},
      note         = {#LA:B062# / 2023 Dec 7;15(12):e18199},
      abstract     = {Brain tumors are the leading cause of cancer-related death
                      in children. Experimental in vitro models that faithfully
                      capture the hallmarks and tumor heterogeneity of pediatric
                      brain cancers are limited and hard to establish. We present
                      a protocol that enables efficient generation, expansion, and
                      biobanking of pediatric brain cancer organoids. Utilizing
                      our protocol, we have established patient-derived organoids
                      (PDOs) from ependymomas, medulloblastomas, low-grade glial
                      tumors, and patient-derived xenograft organoids (PDXOs) from
                      medulloblastoma xenografts. PDOs and PDXOs recapitulate
                      histological features, DNA methylation profiles, and
                      intratumor heterogeneity of the tumors from which they were
                      derived. We also showed that PDOs can be xenografted. Most
                      interestingly, when subjected to the same routinely applied
                      therapeutic regimens, PDOs respond similarly to the
                      patients. Taken together, our study highlights the potential
                      of PDOs and PDXOs for research and translational
                      applications for personalized medicine.},
      keywords     = {brain tumors (Other) / organoids (Other) / patient-derived
                      (Other) / pediatric cancer (Other) / translational
                      applications (Other)},
      cin          = {B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38037472},
      doi          = {10.15252/emmm.202318199},
      url          = {https://inrepo02.dkfz.de/record/285710},
}